UBS O'Connor
FUSN icon

UBS O'Connor’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

UBS O'Connor’s Portfolio FUSN Stock Details FUSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-213,107
Closed -$2.05M – 623
2023
Q4 		$2.05M Sell
213,107
-61,461
-22% -$299K 0.06% 168
2023
Q3 		$714K Hold
274,568
– – 0.01% 364
2023
Q2 		$1.28M Buy
274,568
+32,542
+13% +$141K 0.03% 358
2023
Q1 		$912K Buy
242,026
+51,525
+27% +$203K 0.02% 421
2022
Q4 		$600K Buy
190,501
+173,215
+1,002% +$431K 0.01% 604
2022
Q3 		$52K Buy
+17,286
New +$43.2K ﹤0.01% 860

Other funds holding FUSN

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Avidity Partners Management
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $144B AUM 22.91% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
TPG GP A
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

UBS O'Connor's FUSN Position: Q1 2024 in Review

UBS O'Connor sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q1 2024, closing a stake of 213,107 shares — an estimated $2.05M sold.

UBS O'Connor first reported a position in FUSN in Q3 2022 and held it in 6 quarters. The position peaked at $2.05M in Q4 2023. 114 funds tracked by Wall St. Rank hold FUSN as of Q1 2024.

  • UBS O'Connor reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q1 2024 after selling out during the quarter.
  • UBS O'Connor sold 213,107 Fusion Pharmaceuticals Inc. Common Shares shares in Q1 2024, an estimated $2.05M.
  • UBS O'Connor first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q3 2022 and held it in 6 quarters.
  • UBS O'Connor's Fusion Pharmaceuticals Inc. Common Shares position peaked at $2.05M in Q4 2023.
  • 114 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q1 2024.

Based on UBS O'Connor's 13F filing for Q1 2024, filed 15 May 2024.